First-Generation Antihistamines (H1-Receptor Blockers)

Examples

Diphenhydramine, chlorpheniramine, promethazine, hydroxyzine, cyproheptadine, meclizine, dimenhydrinate, doxylamine, brompheniramine

Mechanism of Action

First-generation H1 antihistamines act as competitive, reversible antagonists at H1 receptors. They do not prevent histamine formation or release; instead, they block receptor-mediated responses in target tissues. They are far more effective at preventing allergic symptoms than reversing them once established.

Key MOA features (via H1 receptor):

Inhibit histamine-induced vascular permeability, smooth muscle contraction, and pruritus
Decrease proinflammatory cytokine release (TNF-α, IL-1β, IL-6, IL-8, GMCSF)
Reduce expression of cell-adhesion molecules (ICAM-1, VCAM-1)
Inhibit eosinophil chemotaxis
Suppress release of preformed mediators (histamine, prostaglandin D₂, platelet-activating factor, tryptase, kinins)

Beyond H1 blockade, first-generation agents (unlike second-generation) also block:

Muscarinic/cholinergic receptors (especially diphenhydramine, promethazine) → anticholinergic effects
α-Adrenergic receptors (especially promethazine) → hypotension
Serotonin receptors (especially cyproheptadine) → appetite stimulation

CNS penetration: These drugs readily cross the blood-brain barrier (they are lipophilic), blocking central H1 receptors — this causes the characteristic sedation and cognitive impairment.

H1 Antihistamines receptor effects diagram

Pharmacokinetics

Well absorbed orally; peak serum levels at 1–2 hours
Duration of action: 4–6 hours (requires dosing q4–8h)
Half-lives of brompheniramine, chlorpheniramine, and hydroxyzine exceed 20 hours in adults
Distributed to all tissues including CNS
Metabolized by hepatic CYP3A4 (glucuronide conjugates, excreted in urine)
Wheal-and-flare suppression may persist up to 7 days after discontinuation

Therapeutic Uses

Use	Notes
Allergic rhinitis, urticaria, angioedema	First-line for histamine-driven symptoms
Motion sickness / nausea	Diphenhydramine, dimenhydrinate, meclizine, promethazine — act on chemoreceptor trigger zone and vestibular pathways via central H1 and M1 blockade
Vertigo	Meclizine
Insomnia	Diphenhydramine, doxylamine (exploiting sedative side effect)
Pruritus (atopic dermatitis, chronic urticaria)	Effective in ~50% of chronic idiopathic urticaria
Anaphylaxis (adjunct)	Note: epinephrine remains the drug of choice
Serotonin syndrome (cyproheptadine)	Due to serotonin-antagonist properties

Side Effects

CNS (most common and clinically significant)

Sedation — the most prominent effect; results from central H1 blockade (CNS neurotransmission reduced)
Cognitive and psychomotor impairment
Dizziness, tinnitus, blurred vision
Irritability, nervousness, insomnia (paradoxical, especially in children)
Tremor
Acute overdose: hallucinations, excitement, ataxia, convulsions → coma → cardiorespiratory collapse

Anticholinergic effects (due to muscarinic receptor blockade)

Dry mouth, dry nasal mucosa
Urinary retention and hesitancy
Constipation
Blurred vision
Postural hypotension, dizziness
Sinus tachycardia / reflex tachycardia
QT prolongation, ventricular arrhythmias, torsades de pointes
Erectile dysfunction

GI (uncommon)

Anorexia, nausea, vomiting, epigastric distress, diarrhea/constipation
(Taking with food reduces these)

Other

Topical formulations → contact dermatitis (local hypersensitivity)

Drug Interactions

Interaction	Result
CNS depressants (alcohol, benzodiazepines, opioids)	Potentiated sedation
MAO inhibitors (e.g., phenelzine)	MAOIs exacerbate both sedative AND anticholinergic effects — combination should be avoided
Cholinesterase inhibitors (donepezil, rivastigmine, galantamine)	First-generation antihistamines reduce effectiveness in Alzheimer's treatment

Contraindications

Contraindication	Reason
Narrow-angle glaucoma	Anticholinergic effects increase intraocular pressure
Concurrent MAOI use	Dangerously potentiated sedative/anticholinergic effects

Risk Factors Requiring Caution (Not Absolute Contraindications)

Prostatic hypertrophy — urinary retention risk (requires close monitoring)
First trimester of pregnancy — potential teratogenicity risk
Cardiac arrhythmias (particularly ventricular arrhythmias) — QT prolongation risk
Occupations requiring wakefulness (drivers, pilots, heavy machinery operators)
Children — paradoxical CNS stimulation; overdose particularly dangerous

— Lippincott Illustrated Reviews: Pharmacology, pp. 1309–1318 — Fitzpatrick's Dermatology, pp. 3482–3485

This is a shared conversation. Sign in to Orris to start your own chat.